Heparin Market 2020 Regional Growth To 2026 By Top Players

Heparin Market report offers in-depth analysis of the industry size, share, major segments, and different geographic regions, forecast for the next five years, key market players, and premium industry trends. It also focuses on the key drivers, restraints, opportunities and industry challenges.

The heparin market is slated to witness considerable growth over the coming years owing to the rising prevalence of chronic illness across the globe. Increasing demand for anticoagulants products is also anticipated to accelerate the overall market share. Furthermore, favorable initiatives undertaken by organizations like the CDC and the NIH (National Institutes of Health) to increase awareness levels through different programs is likely to boost the market outlook in the coming years.

As per a new study, heparin, which is known to be a common blood-thinning medicine, is in fact, being increasingly utilized to treat COVID-19 patients. There is strong evidence that heparin helps in preventing some of the damaging effects of the COVID-19 and even halting the virus from attaching to cells in the body. In July 2020, Rensselaer Polytechnic Institute researchers discovered that heparin was equally as effective at blocking the coronavirus infection in cells for the treatment of COVID-19 than remdesivir. This has greatly catapulted the market value of heparin, which would lucratively drive industry share.

Request for a sample copy of this report @ https://www.gminsights.com/request-sample/detail/4837

As per a GMI, report, heparin market is slated to surpass a $6.6 billion valuation by 2026.   

Low molecular weight heparin segment recorded more than USD 3.6 billion in global revenue in 2019, slated for an exponential growth rate through the coming years. This is owing to the rise in heparin use in surgeries as well as in the treatment of coagulation diseases. Researchers experimenting at the Rensselaer Polytechnic Institute and the University of North Carolina (UNC) have come up with a synthetic, low molecular weight heparin structure that is safe to use. These synthetic products can be reversed during an activity using protamine besides being cost-effective compared to the heparin compounds derived from animals.

Porcine sourced heparin segment contributed to over 98.8% of the overall share in 2019 as it extensively helps in the prevention of blood clots post-surgery, in dialysis and blood transfusion as well as during the collection of the blood samples. The demand can be further attributed to the higher adoption of the porcine based product in patients affected with atrial fibrillation.

Application of heparin in coronary artery diseases was valued at USD 1 billion in 2019 and is pegged to rise over the coming years owing to the consistent prevalence of the disorder in emerging countries. Recurring cases of arterial thrombosis that are caused by damaged arteries may lead to a rise in myocardial infarction and coronary artery issues. This trend is likely to influence the demand for heparin doses.

Heparin anticoagulants witness high distribution across the online, hospital, and retail pharmacies. Online pharmacies offer significant discount rates and access to an extensive range of products along with doorstep delivery, subsequently attracting a larger consumer base. There is a growing popularity among the young and millennial population for online shopping across the developing nations.

 The revenue collected from online segment was annually pegged at 14.7% of the global market share in 2019. The novel coronavirus pandemic could also have influenced the product distribution through pharmacies in recent months.

Request for customization @ https://www.gminsights.com/roc/4837

Asia Pacific heparin industry share will gain significant traction through 2026 due to the prominent presence of local manufacturers across the southeast region, besides the existence of a large patient population in India and China that is vulnerable to chronic ailments. As per reports, venous thromboembolism (VTE) emerged as among the most common ailments affecting Asians in 2017, while the incidence rate of the disorder yearly valued at nearly 100 for every 100,000 in the total population.

Heparin suppliers across the globe are keen on implementing various strategies like acquisitions, launches, and business mergers along with compliance with regulatory policies for the development of the novel products to increase their global presence.

For instance, Amphastar Pharmaceuticals in 2018 launched a new drug application supplement for producing a semi-purified heparin at its subsidiary location. The product also received approval from the U.S. FDA in the same year. Sanofi, Laboratorios Farmaceuticos Rovi SA, Leo Pharma Hepalink group, and Pfizer are a few of the other firms in the sector. 

Partial Chapter of the Table of Content 

Chapter 2   Executive Summary

2.1    Heparin industry 360° synopsis, 2015-2026

2.1.1    Business trends

2.1.2    Product trends

2.1.3    Source trends

2.1.4    Application trends

2.1.5    Distribution channel trends

2.1.6    Regional trends

Chapter 3   Heparin Industry Insights

3.1    Industry segmentation

3.2    Industry landscape, 2015 - 2026

3.3    Industry impact forces

3.3.1    Growth drivers

3.3.1.1    Growing prevalence of chronic diseases

3.3.1.2    High demand for anticoagulants products

3.3.1.3    Rising geriatric population across the globe

3.3.2    Industry pitfalls & challenges

3.3.2.1    High risk of side effects

3.3.2.2    High dependency on porcine

3.4    Growth potential analysis

3.4.1    By product

3.4.2    By source

3.4.3    By application

3.4.4    By distribution channel

3.5    COVID-19 impact analysis

3.6    Porter’s analysis

3.7    Competitive landscape

3.7.1    Company matrix analysis, 2019

3.8    PESTEL analysis 

Browse full table of contents (TOC) of this report @ https://www.gminsights.com/toc/detail/heparin-market